1111 completed, 439 unknown, 389 recruiting, 343 terminated. 2702 Phase 2, 603 Phase 1, 164 Phase 3.
Follow Colonic Diseases: new trials by email Literature Review of Colonic Diseases trials Research Report on Colonic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Impact of a Patient Decision Aid on Treatment Choices for Patients With an Unexpected Malignant Colorectal Polyp Shared Decision Making using a Patient Decision Aid. - Shared Decision Making, Colonic Polyp | Phase 2 | Not yet recruiting | Vejle Hospital | 110 | 2028-02-01 | 2026-04-30 |
| CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer CA102N, TAS-102, Bevacizumab - Metastatic Colorectal Cancer | Phase 2 | Suspended | Holy Stone Healthcare Co., Ltd | 100 | 2027-12-01 | 2026-09-18 |
| Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial Balstilimab, Biopsy Procedure, Biospecimen Collection - Colorectal Adenocarcinoma, Stage II Colorectal Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 20 | 2027-05-25 | 2026-09-29 |
| Efficacy and Safety of TRA16 Administered Orally in Patients With Enteric Hyperoxaluria (EH). TRA16, Placebo - Enteric Hyperoxaluria | Phase 2 | Not yet recruiting | Wuhan Kangfude Urolithiasis Research Institute Co., Ltd. | 30 | 2027-03-01 | 2026-10-13 |
| Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] - Colon Cancer | Phase 2 | Not yet recruiting | John Strickler, M.D. | 24 | 2027-03-01 | 2026-11-05 |
| Alberta Cancer Exercise Dose in Colorectal Cancer Group Exercise Classes - Arm 1, Group Exercise Classes - Arm 2 - Cancer, Colorectal Cancer | Phase 2 | Not yet recruiting | University of Calgary | 90 | 2027-01-01 | 2026-11-06 |
| SAMe in Prevention of Oxaliplatin-associated Liver Injury Standard of care oxaliplatin-based chemotherapy, S-adenosylmethionine (SAMe) supplement, Surgery - Colorectal Cancer, Liver Metastases | Phase 2 | Not yet recruiting | Cedars-Sinai Medical Center | 30 | 2027-01-01 | 2026-11-06 |
| Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer Tovecimig, Irinotecan, Leucovorin - Colorectal Cancer, Metastatic Colorectal Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 25 | 2026-12-31 | 2026-11-05 |
| A Study of DES-1357 in People With Deficient Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer (mCRC) DES-1357 - Metastatic Colorectal Cancer (CRC) | Phase 1 / Phase 2 | Not yet recruiting | D. E. Shaw Research, LLC | 88 | 2026-12-03 | 2026-09-08 |
| A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation LG00313112 - Ovarian Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | LG Chem | 250 | 2026-12-01 | 2026-08-07 |
| HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver | Phase 2 | Not yet recruiting | Mayo Clinic | 80 | 2026-12-01 | 2026-10-05 |
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer varsetatug masetecan, bevacizumab + 5-FU + leucovorin, bevacizumab - Colo-rectal Cancer | Phase 1 / Phase 2 | Not yet recruiting | CytomX Therapeutics | 368 | 2026-12-01 | 2026-10-28 |
| Trastuzumab Rezetecan + Bevacizumab vs. TAS-102 + Bevacizumab in Pretreated mCRC With HER2 Low/Moderate Expression or HER2 Positivity With RAS/BRAF Mutation Trastuzumab Rezetecan (SHR-A1811)+Bevacizumab, Trifluridine/tipiracil hydrochloride tablets (FTD/TPI; TAS-102)+Bevacizumab - Colorectal Cancer | Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 86 | 2026-12-01 | 2026-11-09 |
| Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer Arm1, Arm 2, Arm 3 - CRC (Colorectal Cancer), BRAF | Phase 2 | Not yet recruiting | Sun Yat-sen University | 91 | 2026-11-30 | 2026-07-21 |
| Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer Pembrolizumab, Porustobart - Colon Cancer | Phase 2 | Recruiting | Solstice Oncology, Inc. | 100 | 2026-11-30 | 2026-11-12 |
| Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors REGN13089-M404-M2980 - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 320 | 2026-11-23 | 2026-10-07 |
| FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II) Oxaliplatin, 5-Fluorouracil, Levofolinic Acid For Injection - Metastatic Colorectal Cancer (CRC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 229 | 2026-11-01 | 2026-10-16 |
| Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer AlloStim, Bavencio - Metastatic Colorectal Cancer | Phase 2 | Withdrawn | Mirror Biologics, Inc. | 2026-11-01 | 2025-10-21 | |
| Aquamin® for Prevention of Ulcerative Colitis J-Pouch-associate Intestinal Inflammation Aquamin - Ulcerative Colitis, Ileal Pouch | Phase 2 | Recruiting | Muhammad N Aslam, MD | 52 | 2026-11-01 | 2026-11-02 |
Showing 20 of 2702. Sign in to see all of them.
Colorectal Neoplasms (1873) · Colonic Neoplasms (603) · Rectal Neoplasms (358) · Colitis, Ulcerative (345) · Neoplasm Metastasis (207) · Pancreatic Neoplasms (162) · Carcinoma, Non-Small-Cell Lung (155) · Neoplasms (145) · Irritable Bowel Syndrome (136) · Breast Neoplasms (129) · Stomach Neoplasms (127) · Ovarian Neoplasms (105) · Lung Neoplasms (95) · Inflammatory Bowel Diseases (83) · Melanoma (80)
Digestive System Diseases (2681) · Intestinal Diseases (2679) · Gastrointestinal Diseases (2671) · Neoplasms by Site (2180) · Digestive System Neoplasms (2175) · Intestinal Neoplasms (2172) · Gastrointestinal Neoplasms (2140) · Neoplasms (2062) · Rectal Diseases (1957) · Pathological Conditions, Signs and Symptoms (382) · Gastroenteritis (375) · Colitis (328) · Colorectal Neoplasms (322) · Neoplasms by Histologic Type (310)
Oxaliplatin (314) · Bevacizumab (311) · Fluorouracil (301) · Irinotecan (293) · Leucovorin (270) · Capecitabine (223) · Cetuximab (222) · Panitumumab (91) · pembrolizumab (88) · Folfox protocol (77) · Nivolumab (62) · regorafenib (61) · HMPL-013 (54) · IFL protocol (54) · Radiotherapy (50)
National Cancer Institute (NCI) (88) · Fudan University (53) · Sun Yat-sen University (50) · M.D. Anderson Cancer Center (40) · Eli Lilly and Company (31) · Memorial Sloan Kettering Cancer Center (30) · Pfizer (29) · Hoffmann-La Roche (26) · Amgen (24) · AstraZeneca (21) · Alliance for Clinical Trials in Oncology (18) · Bristol-Myers Squibb (18) · GlaxoSmithKline (18) · Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) (18) · Roswell Park Cancer Institute (17)
United States (1158) · China (487) · France (289) · Spain (253) · Canada (246) · Italy (243) · Germany (239) · United Kingdom (201) · Belgium (178) · South Korea (159) · Poland (157) · Netherlands (143) · Australia (140) · Japan (122) · Hungary (106)
Norman Wolmark, MD (8) · Leonard B. Saltz, MD (6)
PMID 28712102, PMID 37934000, PMID 38592721, PMID 30721964, PMID 31401903, PMID 32816630, PMID 36657089, PMID 40341199, PMID 15496622, PMID 18316791, PMID 22070868, PMID 23493136, PMID 26049686, PMID 26755520, PMID 26893500, PMID 27389519, PMID 27789196, PMID 28103904, PMID 28596308, PMID 29398921, PMID 31527168, PMID 31803504, PMID 31982148, PMID 32698790, PMID 33416261, PMID 33607964, PMID 34213592, PMID 34289971, PMID 34606846, PMID 35100697, PMID 35588252, PMID 36880426, PMID 37119510, PMID 37162250, PMID 38564700, PMID 39475591, PMID 39778975, PMID 40056080, PMID 41359652, PMID 9146781, PMID 10400410, PMID 10493478, PMID 10744089, PMID 11171826, PMID 11239312, PMID 11247898, PMID 11413430, PMID 11491192, PMID 11762804, PMID 11914441
2023 (40), 2017 (35), 2025 (33), 2016 (26), 2018 (24), 2009 (23), 2019 (19), 2008 (16), P30CA015083 (14), 2014 (13), 2015 (13), P30CA033572 (9), P30CA016672 (8), P30CA060553 (8), U10CA032102 (6)